Forecasting COVID-19 cases in US states using reconstructed incidence data
Branching process models are commonly used in infectious disease forecasting and often rely on daily incidence data, but their utility can be restricted if incidence is not reported daily or if reporting becomes less frequent during prolonged outbreaks. In this study, an Expectation Maximisation algorithm is used to reconstruct the daily incidence of COVID-19 cases from weekly case counts. Using data from 13 US states that maintained mostly daily reporting of COVID-19 cases from March 2020 to February 2022, we evaluate forecasting performance by comparing models using the true daily incidence with those using reconstructed daily incidence. Our results show that forecasts generated from reconstructed incidence perform equally well as those generated using true daily incidence. These findings demonstrate the viability of using reconstructed incidence data for real-time forecasting, which could be particularly useful in scenarios where maintaining daily reporting is unsustainable or in settings with limited surveillance capacity.
Authors
- Anne Cori (ORCID: https://orcid.org/0000-0002-8443-9162)
- Rebecca K. Nash (ORCID: https://orcid.org/0000-0002-5213-4364)
- Sangeeta Bhatia (ORCID: https://orcid.org/0000-0001-6525-101X)
- Pierre Nouvellet (ORCID: https://orcid.org/0000-0002-6094-5722)
- Jack Wardle (ORCID: https://orcid.org/0000-0002-5363-1653)
Institutions
- University of Sussex (GB)
- Imperial College London (GB)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-08-24
- DOI
- https://doi.org/10.1371/journal.pone.0353983
- Primary Topic
- COVID-19 epidemiological studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- London School of Hygiene and Tropical Medicine
- Wellcome Trust
- National Institute for Health Research Health Protection Research Unit
- National Institute for Health and Care Research
- British Heart Foundation
- Department of Health and Social Care
- Diabetes UK
- Academy of Medical Sciences
- Imperial College London
- Medical Research Council
- European and Developing Countries Clinical Trials Partnership